Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

[Biomarkers of endothelial dysfunction and risk of early organ damage: a comparison between patients with primary aldosteronism and essential hypertension].

Liu G, Zhang SL, Liu PM, Yin GS, Tang JY, Ma DJ, Yan L, Wang JF.

Zhonghua Xin Xue Guan Bing Za Zhi. 2012 Aug;40(8):640-4. Chinese.

PMID:
23141006
2.

Endothelial dysfunction in patients with primary aldosteronism: a biomarker of target organ damage.

Liu G, Yin GS, Tang JY, Ma DJ, Ru J, Huang XH.

J Hum Hypertens. 2014 Dec;28(12):711-5. doi: 10.1038/jhh.2014.11. Epub 2014 Feb 20.

PMID:
24553636
3.

Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy.

Lip GY, Blann AD, Jones AF, Lip PL, Beevers DG.

Am J Cardiol. 1997 Dec 15;80(12):1566-71.

PMID:
9416937
4.

Impact of essential hypertension and primary aldosteronism on plasma brain natriuretic peptide concentration.

Jakubik P, Janota T, Widimsky J Jr, Zelinka T, Strauch B, Petrak O, Benakova H, Bezdickova D, Wichterle D, Zima T, Hradec J.

Blood Press. 2006;15(5):302-7.

PMID:
17380848
5.

[Comparison on metabolic disorders and uric acid levels between patients with primary aldosteronism and essential hypertension].

Deng YJ, Zhang SL, Liu PM, Mai LF, Tang JY, Yan L.

Zhonghua Xin Xue Guan Bing Za Zhi. 2016 Sep 24;44(9):743-749. doi: 10.3760/cma.j.issn.0253-3758.2016.09.003. Chinese.

PMID:
27667270
6.

Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension.

Cerasola G, Cottone S, Mulé G, Nardi E, Mangano MT, Andronico G, Contorno A, Li Vecchi M, Galione P, Renda F, Piazza G, Volpe V, Lisi A, Ferrara L, Panepinto N, Riccobene R.

J Hypertens. 1996 Jul;14(7):915-20.

PMID:
8818932
7.

Twenty-four-hour urinary aldosterone predicts inappropriate left ventricular mass index in patients with primary aldosteronism.

Hung CS, Ho YL, Chang YY, Wu VC, Wu XM, Lee JK, Chueh SC, Lin YH, Changh YS, Yang SY, Hu YH, Sui MJ, Chen MF, Wu KD.

ScientificWorldJournal. 2013 Dec 29;2013:294594. doi: 10.1155/2013/294594. eCollection 2013.

8.
9.

C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk.

Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD.

Arterioscler Thromb Vasc Biol. 2002 Apr 1;22(4):593-8.

10.

Albuminuria in untreated patients with primary aldosteronism or essential hypertension.

Halimi JM, Mimran A.

J Hypertens. 1995 Dec;13(12 Pt 2):1801-2.

PMID:
8903655
12.

Role of aldosterone in left ventricular hypertrophy in hypertension.

Matsumura K, Fujii K, Oniki H, Oka M, Iida M.

Am J Hypertens. 2006 Jan;19(1):13-8.

PMID:
16461184
13.

[Association of microalbuminuria and von Willebrand factor with metabolic syndrome in hypertensive patients].

Liu J, Yang J, Sun NL.

Beijing Da Xue Xue Bao. 2007 Dec 18;39(6):587-90. Chinese.

14.

Endothelial progenitor cells in primary aldosteronism: a biomarker of severity for aldosterone vasculopathy and prognosis.

Wu VC, Lo SC, Chen YL, Huang PH, Tsai CT, Liang CJ, Kuo CC, Kuo YS, Lee BC, Wu EL, Lin YH, Sun YY, Lin SL, Chen JW, Lin SJ, Wu KD; TAIPAI Study Group.

J Clin Endocrinol Metab. 2011 Oct;96(10):3175-83. doi: 10.1210/jc.2011-1135. Epub 2011 Aug 3.

PMID:
21816781
15.
16.

[B-type natriuretic peptides and subclinical target organ damage in essential hypertensive patients].

Peng XL, Lin ZP, Zhang RK, Zhang ZW.

Nan Fang Yi Ke Da Xue Xue Bao. 2010 Oct;30(10):2347-50. Chinese.

17.

[Target organ damage in children with newly diagnosed and untreated essential hypertension].

Antoniewicz J, Litwin M, Daszkoska J, Niemirska A, Sladowska J, Wierzbicka A, Wawer Z, Grenda R.

Przegl Lek. 2006;63 Suppl 3:101-6. Polish.

PMID:
16898502
18.

Plasma concentrations of von Willebrand factor and intracellular adhesion molecule-1 for prediction of outcome after successful cardiopulmonary resuscitation.

Geppert A, Zorn G, Delle-Karth G, Koreny M, Siostrzonek P, Heinz G, Huber K.

Crit Care Med. 2003 Mar;31(3):805-11.

PMID:
12626988
19.

Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension.

Strauch B, Petrák O, Wichterle D, Zelinka T, Holaj R, Widimský J Jr.

Am J Hypertens. 2006 Sep;19(9):909-14.

PMID:
16942932
20.

Primary aldosteronism and essential hypertension: assessment of cardiovascular risk at diagnosis and after treatment.

Turchi F, Ronconi V, di Tizio V, Ceccoli L, Boscaro M, Giacchetti G.

Nutr Metab Cardiovasc Dis. 2014 May;24(5):476-82. doi: 10.1016/j.numecd.2013.09.009. Epub 2013 Nov 2.

PMID:
24630976

Supplemental Content

Support Center